CHD5 has previously been proposed as a tumour suppressor, acting as a brake that prevents healthy cells from developing into cancer cells. But the part played by the protein in healthy tissue, and whether this role is important for its ability to counter tumour growth, has remained largely uncharted. Working with colleagues at Trinity College in Dublin and BRIC in Copenhagen, researchers at Karolinska Institutet have revealed its function in normal nervous system development and as a tumour suppressor.
The recently published study shows that when stem cells approach the final phase of their specialisation as neurons, CHD5 begins to be expressed at high levels. CHD5 can reshape the chromatin, in which DNA is packed around proteins, and in so doing either facilitate or obstruct the expression of genes. Ulrika Nyman, postdoc researcher in Dr Johan Holmberg's research group and one of the main authors of the current study, explains that on switching off CHD5 in the stem cells of mice embryos during the period in which the brain develops and the majority of neurons are formed, they found was that without CHD5, a stem cell is unable to silence the expression of a number of stem cell genes and genes that are actually to be expressed in muscle, blood or intestinal cells. They also observed an inability in the stem cell to switch on the expression of genes necessary for it to mature into a neuron, leaving it trapped in a stage between stem cell and neuron.
The gene that codes for CHD5 is found on part of chromosome 1 (1p36), which is often lost in tumour cells in a number of cancers, particularly neuroblastoma, a disease that strikes almost only children and which is thought to arise during the development of the peripheral nervous system. Neuroblastoma lacking this section of chromosome and thus also CHD5 are often more aggressive and more rapidly fatal. Treatment with retinoic acid can make immature nerve cells and some neuroblastoma cells mature into specialised nerve cells, but when the researchers prevented neuroblastoma cells from upregulating CHD5, the tumours no longer responded to retinoic acid treatment.
"In the absence of CHD5, neural tumour cells cannot mature into harmless neurons, but continue to divide, making the tumour more malignant and much harder to treat," says Dr Holmberg at the Department of Cell and Molecular Biology. "We now hope to be able to restore the ability to upregulate CHD5 in aggressive tumour cells and make them mature into harmless nerve cells."
The research group at Karolinska Institutet is also active at the Ludwig Institute for Cancer Research. The study was financed by grants from the Swedish Research Council, the Swedish Cancer Society, the Children's Cancer Foundation and the Lilian Sagen and Curt Eriksson Research Foundation.
Publication: Egan et al., CHD5 Is Required for Neurogenesis and Has a Dual Role in Facilitating Gene Expression and Polycomb Gene Repression, Developmental Cell (2013), http://dx.doi.org/10.1016/j.devcel.2013.07.008
For further information, contact:
Johan Holmberg, research associate
Department of Cell and Molecular Biology & the Ludwig Institute for Cancer Research
Tel: +46 (0)8 524 871 08 or +46 (0)72 221 27 02
Contact the Press Office
Tel: +46 (0)8 524 860 77
Karolinska Institutet is one of the world's leading medical universities. It accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.